Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD). While intravenous (IV) ketamine has been the most common parenteral route of administration, subcutaneous (SC) and intramuscular options have been described. We developed a clinical treatment protocol for the use of repeated SC racemic ketamine...
Joseph C.W. Tham, André Do, Jason Fridfinnson et al.
preprint
Intravenous (IV) ketamine has been shown to have rapid antidepressant effects in individuals with treatment-resistant depression (TRD). This treatment protocol describes a clinical method for use of subcutaneous (SC) and intramuscular (IM) racemic ketamine in individuals with TRD, developed by a team at the University of British Columbia (UBC), UBC Hospital, and Vancouver General Hospital. The...